Medicine and Dentistry
Dolutegravir
100%
Integrase
68%
Next Generation Sequencing
62%
Human Immunodeficiency Virus
37%
Infection
37%
Cells
31%
Sanger Sequencing
25%
Patient Compliance
25%
Patient
25%
DNA Binding
25%
Assay
18%
Drug
18%
Chemotherapeutic Agent
18%
Observation
18%
Deterioration
12%
Virus
12%
Lamivudine
12%
Case Report
12%
Fitness
12%
Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry
12%
Drug Resistance
12%
Human Immunodeficiency Virus Type 1 Subtype B
12%
Binding Affinity
12%
Prevalence
12%
Blood Cell
12%
Protein
12%
Development
12%
Virus Genome
12%
Plasma
6%
Therapeutic Procedure
6%
Association
6%
Rebound
6%
Diagnostic Error
6%
Abacavir
6%
Pimeprofen
6%
Mutant
6%
RNA Directed DNA Polymerase
6%
Clinical Management
6%
Pharmacology, Toxicology and Pharmaceutical Science
Dolutegravir
62%
Integrase
50%
Tenofovir Disoproxil
46%
Aciclovir
37%
HIV
35%
Drug Resistance
33%
Nonnucleoside Reverse Transcriptase Inhibitor
27%
Infection
25%
DNA
25%
Enalapril Maleate
22%
Tenofovir
15%
Emtricitabine
15%
Human Immunodeficiency Virus 1 Infection
14%
HIV Drug Resistance
12%
Human Immunodeficiency Virus Type 1 Subtype B
12%
Integrase Inhibitor
12%
Drug
12%
Prevalence
12%
Protein
12%
Lamivudine
6%
Cross-Resistance
6%
Virus
6%
Clinical Trial
6%
Human Immunodeficiency Virus 1
6%
Base
6%
Biochemistry, Genetics and Molecular Biology
Integrase
81%
Mutation
56%
Human Immunodeficiency Virus
50%
Patient Compliance
25%
Virus Load
25%
DNA Binding
25%
Drug Resistance
25%
DNA
25%
Sequencing
18%
Lamivudine
12%
Fitness
12%
Virus
12%
Human Immunodeficiency Virus Type 1 Subtype B
12%
Clone
12%
Prevalence
12%
Protein
12%
Binding Affinity
12%
Development
12%
Virus Genome
12%
Association
6%
Abacavir
6%
Reverse Transcriptase
6%
Rebound
6%
Mutant
6%
Blood Level
6%